Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Understanding the Impact of Regional Regulations on Medical Device Development in California

Apr 04, 2025

Introduction

California, known for its innovation and technological advancements, is a major hub for medical device development. However, the state's unique regulatory environment significantly impacts how these devices are developed and brought to market. Understanding these regulations is crucial for medical device companies aiming to succeed in this competitive space.

california landscape

The Role of the FDA and State Regulations

The U.S. Food and Drug Administration (FDA) plays a critical role in the regulation of medical devices across the country. Yet, in California, state-specific regulations can add additional layers of complexity. While the FDA sets broad federal guidelines, California's state regulations may impose stricter requirements on certain types of devices or testing procedures.

For instance, medical device companies in California must navigate both federal and state requirements when it comes to clinical trials and product testing. This dual-regulatory landscape requires companies to be well-versed in both sets of regulations to ensure compliance and avoid costly delays.

Environmental Considerations

California's stringent environmental policies also impact medical device development. The state is known for its progressive environmental laws that aim to reduce waste and promote sustainable practices. Medical device manufacturers must consider these regulations during the design and production phases to ensure their products meet the state's environmental standards.

eco friendly manufacturing

These environmental regulations can influence decisions such as the types of materials used in device production and the methods of disposal for medical waste. Companies that prioritize eco-friendly practices not only comply with regulations but also appeal to environmentally conscious consumers.

Impact on Innovation

While some may view California's regulatory environment as a challenge, it can also be seen as a driver of innovation. The need to comply with strict regulations often leads companies to develop cutting-edge technologies and processes that set them apart from competitors. This has helped California maintain its status as a leader in the medical device industry.

By fostering an environment that encourages innovation while maintaining high standards, California continues to attract top talent and investment in the medical sector. This dynamic ecosystem supports the development of groundbreaking medical devices that have a global impact.

medical innovation

Navigating Regulatory Challenges

For companies new to the California medical device market, understanding and navigating the regulatory landscape can be daunting. Many firms opt to partner with regulatory consultants or legal experts who specialize in California’s unique requirements. These professionals can provide invaluable guidance and help streamline the approval process.

Additionally, maintaining open communication with regulatory bodies and staying abreast of any changes in legislation can help companies remain compliant and avoid potential pitfalls. This proactive approach is vital for sustaining success in the competitive landscape of medical device development.

Conclusion

Ultimately, understanding the impact of regional regulations on medical device development in California is essential for any company looking to thrive in this sector. By embracing these regulations as opportunities for innovation rather than obstacles, companies can not only achieve compliance but also drive industry advancements. As California continues to lead in medical technology, staying informed and adaptable will be key to leveraging the full potential of this dynamic market.